Thomas Guiot Selected Research

Thomas Guiot Research Topics

11	Neoplasms (Cancer) 04/2024 - 01/2015
8	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 01/2015
6	Breast Neoplasms (Breast Cancer) 04/2024 - 08/2017
1	Pathologic Complete Response 04/2024
1	Prostatic Neoplasms (Prostate Cancer) 09/2023
1	Circulating Neoplastic Cells 09/2020
1	Neoplasm Metastasis (Metastasis) 07/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 07/2015

7	Biomarkers (Surrogate Marker)IBA 09/2023 - 01/2015
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 08/2017
3	Trastuzumab (Herceptin)FDA Link 04/2024 - 08/2017
2	Proteins (Proteins, Gene)FDA Link 04/2024 - 08/2017
2	pertuzumabIBA 04/2024 - 04/2024
2	human ERBB2 proteinIBA 04/2024 - 08/2017
2	Phenobarbital (Luminal)FDA Link 03/2022 - 09/2021
2	Everolimus FDA Link 03/2022 - 09/2021
2	regorafenibIBA 12/2021 - 03/2015
2	Cell-Free Nucleic AcidsIBA 09/2020 - 10/2019
1	Hormones (Hormone)IBA 04/2024
1	ErbB Receptors (EGF Receptor)IBA 01/2024
1	Ado-Trastuzumab EmtansineIBA 01/2024
1	zirconium-89-trastuzumabIBA 01/2024
1	AntigensIBA 09/2023
1	cabazitaxel FDA Link 09/2023
1	coriolanIBA 09/2020
1	Carcinoembryonic AntigenIBA 09/2020
1	SirtuinsIBA 07/2018
1	Expectorants (Mucolytics)IBA 08/2017
1	Glucose (Dextrose)FDA LinkGeneric 08/2017
1	Sorafenib (BAY 43-9006)FDA Link 09/2016
1	Capecitabine (Xeloda)FDA Link 09/2016
1	Rituximab (Mabthera)FDA Link 07/2015